Similarly, Liu et al. (VIP study) found that among 871 patients receiving anti-TNF therapy and 417 patients receiving vedolizumab therapy, there were significant reductions in anti-S-IgG levels and increased breakthrough infections after a third vaccination when anti-TNF agents were used [27]. The gene discussed is TNF; the disease is infection.